Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Over the last 12 months, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $295.75M worth of Regeneron Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Regeneron Pharmaceuticals, Inc. have bought $0 and sold $2.65B worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 105,820 shares for transaction amount of $51.01M was made by Sanofi (10 percent owner) on 2017‑08‑24.
2024-06-24 | Sale | Bassler Bonnie L | director | 756 0.0007% | $1,062.00 | $802,872 | +0.69% | |
2024-06-14 | Sale | BROWN MICHAEL S | director | 1,535 0.0015% | $1,040.00 | $1.6M | +1.23% | |
2024-06-12 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 16,149 0.015% | $1,015.94 | $16.41M | +1.67% | |
2024-06-11 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 9,064 0.0084% | $1,015.43 | $9.2M | +3.35% | |
2024-06-06 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 787 0.0007% | $1,015.02 | $798,821 | +3.70% | |
2024-06-05 | Sale | Bassler Bonnie L | director | 827 0.0008% | $1,011.00 | $836,097 | +3.05% | |
2024-06-03 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $994.50 | $99,450 | +3.88% | |
2024-06-03 | Sale | McCourt Marion | EVP Commercial | 1,138 0.001% | $980.16 | $1.12M | +3.88% | |
2024-05-28 | Sale | BROWN MICHAEL S | director | 1,172 0.0011% | $974.86 | $1.14M | +3.96% | |
2024-05-21 | Sale | LAROSA JOSEPH J | EVP General Counsel and Secret | 1,865 0.0017% | $994.90 | $1.86M | +0.86% | |
2024-05-17 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 22,830 0.0212% | $979.23 | $22.36M | +1.93% | |
2024-05-16 | Sale | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 50,000 0.046% | $972.73 | $48.64M | +3.44% | |
2024-05-15 | Sale | YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 50,000 0.046% | $975.87 | $48.79M | +2.31% | |
2024-05-15 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 10,941 0.0101% | $980.34 | $10.73M | +2.31% | |
2024-05-14 | Sale | SCHLEIFER LEONARD S | Bd. Co-Chair, President & CEO | 25,000 0.0229% | $979.25 | $24.48M | +1.31% | |
2024-05-01 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $899.61 | $89,961 | +9.03% | |
2024-05-01 | Sale | McCourt Marion | EVP Commercial | 250 0.0002% | $889.41 | $222,353 | +9.03% | |
2024-04-01 | Sale | RYAN ARTHUR F | director | 100 <0.0001% | $962.53 | $96,253 | +0.06% | |
2024-04-01 | Sale | McCourt Marion | EVP Commercial | 250 0.0002% | $964.73 | $241,183 | +0.06% | |
2024-03-14 | Sale | MURPHY ANDREW J | EVP Research | 5,783 0.0053% | $956.47 | $5.53M | +0.82% |
YANCOPOULOS GEORGE | Bd. Co-Chair, President & CSO | 786383 0.1668% | $1,069.16 | 0 | 29 | |
MURPHY ANDREW J | EVP Research | 48306 0.055% | $1,069.16 | 0 | 13 | |
STAHL NEIL | EVP Research and Development | 52019 0.0482% | $1,069.16 | 0 | 44 | |
LAROSA JOSEPH J | EVP General Counsel and Secret | 34678 0.0357% | $1,069.16 | 0 | 15 | |
Landry Robert E | EVP Finance CFO | 31699 0.0294% | $1,069.16 | 0 | 43 | |
SING GEORGE L | director | 26349 0.0244% | $1,069.16 | 2 | 49 | +19.37% |
Van Plew Daniel P | EVP & General Mgr, Industrial | 20378 0.0199% | $1,069.16 | 0 | 25 | |
RYAN ARTHUR F | director | 17982 0.017% | $1,069.16 | 1 | 56 | +15.03% |
Fenimore Christopher R. | SVP Finance & CFO | 14372 0.0133% | $1,069.16 | 0 | 13 | |
McCourt Marion | EVP Commercial | 12931 0.0128% | $1,069.16 | 0 | 44 | |
SCHLEIFER LEONARD S | President & CEO | 0 0.0128% | $1,069.16 | 0 | 34 | |
GOLDSTEIN JOSEPH L | director | 6382 0.0059% | $1,069.16 | 0 | 78 | |
POON CHRISTINE A | director | 2037 0.0019% | $1,069.16 | 2 | 5 | +28.16% |
Bassler Bonnie L | director | 1382 0.0013% | $1,069.16 | 0 | 19 | |
Zoghbi Huda Y | director | 1247 0.0012% | $1,069.16 | 0 | 9 | |
BROWN MICHAEL S | director | 1382 0.0012% | $1,069.16 | 0 | 70 | |
Sanofi | 10 percent owner | 279766 0.2592% | $1,069.16 | 53 | 7 | +15.98% |
GOLDBERG MURRAY A | SVP Administration & Asst Secr | 63102 0.0585% | $1,069.16 | 0 | 38 | |
VAGELOS P ROY | 23461 0.0217% | $1,069.16 | 0 | 44 | ||
Terifay Robert J | EVP Commercial | 23293 0.0216% | $1,069.16 | 0 | 15 | |
ROBERTS WILLIAM | VP Reg Dev & Med Safety | 20644 0.0191% | $1,069.16 | 0 | 23 | |
Powchik Peter | SVP Clinical Development & Reg | 15821 0.0147% | $1,069.16 | 0 | 14 | |
KOLINSKI STUART | SVP General Counsel and Secret | 10613 0.0098% | $1,069.16 | 0 | 9 | |
GULER HANS PETER | VP Clinical Programs | 10530 0.0098% | $1,069.16 | 0 | 2 | |
BAKER CHARLES A | director | 9000 0.0083% | $1,069.16 | 0 | 17 | |
GILMAN ALFRED G | director | 8912 0.0083% | $1,069.16 | 0 | 15 | |
McCorkle Douglas S | VP Controller and Asst Treasur | 6866 0.0064% | $1,069.16 | 0 | 24 | |
Aberman Michael S | SVP Strategy Investor Relation | 4693 0.0043% | $1,069.16 | 0 | 14 | |
RUPP RANDALL | SVP, Manufuring Operations | 3983 0.0037% | $1,069.16 | 0 | 10 | |
Tessier-Lavigne Marc | 2593 0.0024% | $1,069.16 | 0 | 11 | ||
INGRAM ROBERT ALEXANDER | director | 1500 0.0014% | $1,069.16 | 0 | 1 | |
COLES N ANTHONY | director | 1093 0.001% | $1,069.16 | 0 | 5 | |
SHOOTER ERIC M | director | 0 0% | $1,069.16 | 0 | 19 | |
NOVARTIS PHARMA AG | 10 percent owner | 0 0% | $1,069.16 | 0 | 1 |
Fidelity Investments | $10.39B | 9.8 | 10.79M | +4.62% | +$458.78M | 0.7 | |
The Vanguard Group | $8.6B | 8.11 | 8.93M | +1.04% | +$88.51M | 0.16 | |
BlackRock | $8.25B | 7.78 | 8.57M | -0.71% | -$58.76M | 0.19 | |
JPMorgan Chase | $7.44B | 7.01 | 7.73M | +6.92% | +$481.63M | 0.67 | |
State Street | $4.66B | 4.39 | 4.84M | -1.22% | -$57.46M | 0.2 | |
Capital World Investors | $4.48B | 4.22 | 4.65M | -9.27% | -$457.79M | 0.74 | |
Capital International Investors | $3.01B | 2.84 | 3.13M | +7.31% | +$205.05M | 0.61 | |
Geode Capital Management | $2.28B | 2.16 | 2.38M | +0.95% | +$21.49M | 0.21 | |
Dodge & Cox | $2.27B | 2.14 | 2.36M | -0.33% | -$7.52M | 1.32 | |
Franklin Templeton Investments | $1.63B | 1.54 | 1.69M | +249.98% | +$1.16B | 0.49 | |
Morgan Stanley | $1.29B | 1.22 | 1.34M | +17.55% | +$192.48M | 0.1 | |
Loomis, Sayles & Company | $1.16B | 1.1 | 1.21M | -0.97% | -$11.43M | 1.68 | |
Wellington Management Company | $1.05B | 0.99 | 1.09M | -0.83% | -$8.77M | 0.18 | |
Amundi | $944.63M | 0.96 | 1.06M | +15.57% | +$127.27M | 0.4 | |
Northern Trust | $954.28M | 0.9 | 991,465 | -5.25% | -$52.88M | 0.16 | |
Invesco | $949.08M | 0.9 | 986,068 | +28.9% | +$212.77M | 0.2 | |
Legal & General | $941.26M | 0.89 | 977,941 | -0.77% | -$7.31M | 0.22 | |
T. Rowe Price | $868.76M | 0.82 | 902,613 | +25.7% | +$177.64M | 0.11 | |
BNY Mellon | $853.29M | 0.81 | 886,544 | -6.54% | -$59.7M | 0.16 | |
Bank of America | $850.91M | 0.8 | 884,068 | +0.64% | +$5.44M | 0.08 | |
American Century Investments | $848.83M | 0.8 | 881,905 | -5.31% | -$47.57M | 0.52 | |
AllianceBernstein | $708.91M | 0.67 | 736,533 | -1.03% | -$7.4M | 0.25 | |
Ubs Asset Management Americas Inc | $658.89M | 0.62 | 684,564 | +2.73% | +$17.5M | 0.24 | |
Charles Schwab | $614.28M | 0.58 | 638,223 | +2.84% | +$16.95M | 0.14 | |
Dimensional Fund Advisors | $566.86M | 0.54 | 588,953 | -0.77% | -$4.4M | 0.15 | |
Nuveen | $518.54M | 0.49 | 538,750 | +20.13% | +$86.89M | 0.15 | |
Massachusetts Financial Services Co Ma | $462.5M | 0.44 | 480,524 | +98.28% | +$229.24M | 0.14 | |
Neuberger Berman | $434.74M | 0.41 | 451,684 | -3.05% | -$13.67M | 0.36 | |
CalPERS | $391.79M | 0.37 | 407,058 | -1.32% | -$5.24M | 0.28 | |
Capital Research Global Investors | $379.4M | 0.36 | 394,182 | -3.01% | -$11.76M | 0.09 | |
Goldman Sachs | $366.63M | 0.35 | 380,921 | +2.46% | +$8.79M | 0.07 | |
HSBC | $363.17M | 0.34 | 377,426 | +16.13% | +$50.43M | 0.26 | |
Global Assets Advisory Llc | $364,000.00 | 0.32 | 352,829 | New | +$364,000.00 | 0.02 | |
Barclays | $330.73M | 0.31 | 343,618 | +15.22% | +$43.68M | 0.15 | |
The Manufacturers Life Insurance Company | $325.61M | 0.31 | 338,296 | -0.4% | -$1.31M | 0.3 | |
First Trust | $323.85M | 0.31 | 336,472 | -8.05% | -$28.37M | 0.33 | |
Ameriprise Financial | $319.96M | 0.3 | 332,545 | -0.98% | -$3.18M | 0.09 | |
Swiss National Bank | $308.77M | 0.29 | 320,800 | -3.9% | -$12.51M | 0.21 | |
Sumitomo Mitsui Trust Holdings | $307.08M | 0.29 | 319,048 | -0.09% | -$289,709.49 | 0.21 | |
Deutsche Bank | $300.37M | 0.28 | 312,076 | -4.09% | -$12.82M | 0.14 | |
Td Asset Management Inc | $259.4M | 0.25 | 269,511 | +162.9% | +$160.73M | 0.23 | |
UBS | $247.82M | 0.23 | 257,481 | +90.82% | +$117.95M | 0.08 | |
Chevy Chase Trust Holdings Inc | $233.29M | 0.22 | 242,380 | -2.88% | -$6.93M | 0.76 | |
D. E. Shaw & Co. | $221.83M | 0.21 | 230,471 | -36.69% | -$128.58M | 0.3 | |
Bank of Montreal | $221.54M | 0.21 | 229,053 | -19.68% | -$54.27M | 0.07 | |
De Depot Et Placement Du Quebec Caisse | $219.45M | 0.21 | 228,001 | -12.36% | -$30.96M | 0.53 | |
DekaBank | $212.63M | 0.2 | 221,176 | -1.34% | -$2.89M | 0.4 | |
Standard Life | $211.99M | 0.2 | 220,249 | +0.16% | +$335,909.01 | 0.42 | |
Candriam S C A | $209.6M | 0.2 | 217,771 | -9.87% | -$22.95M | 1.35 | |
Marshall Wace | $192.87M | 0.18 | 200,387 | +111.99% | +$101.89M | 0.25 |